Precision BioSciences (NASDAQ:DTIL) saw its stock rise 5% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to its PBGENE-DMD therapy for ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Precision BioSciences is also currently evaluating PBGENE-PMM, a first-of-its-kind treatment for m.3243 associated mitochondrial disease, in pre-clinical studies.

He also will become member of the Precision BioSciences Board of Directors, in each case effective October 15, 2021. Mr. Amoroso will succeed Matt Kane, Co-Founder, President and Chief Executive ...

Precision BioSciences, Inc. (NASDAQ:DTIL) missed earnings with its latest yearly results, disappointing overly-optimistic analysts. Precision BioSciences missed analyst estimates, with revenues of ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $60.00. Patrick Trucchio’s rating is based on ...

DURHAM – Precision Biosciences has inked a deal with gene editing company iECURE to advance one of Precision’s drug candidates into Phase 1 clinical studies. The agreement also gives iECURE a ...

Introduction. Precision BioSciences (NASDAQ:DTIL) is a genome editing company dedicated to improving life through their proprietary genome editing platform (“ARCUS”), where they are developing ...

BGENE-DMD is designed to treat Duchenne muscular dystrophy (DMD) via a one-time administration in a single AAV.

Investing.com -- Precision BioSciences (NASDAQ: DTIL) stock rose 5% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its PBGENE-DMD ...